Sample | Title | Value | Rank |
GSM1256968 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 1 | 176.367 | 84 |
GSM1256969 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 2 | 209.843 | 86 |
GSM1256970 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 3 | 201.603 | 85 |
GSM1256971 | SLE-patients; Group 3: CD16pos, resident monocytes; active SLE 4 | 238.259 | 87 |
GSM1256988 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 55 before YFV | 223.452 | 86 |
GSM1256991 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 55 seven days after YFV | 240.2 | 87 |
GSM1256989 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 56 before YFV | 246.068 | 87 |
GSM1256992 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 56 seven days after YFV | 213.09 | 86 |
GSM1256990 | Yellow fever vaccinated NDs; Group 8: CD16pos, resident monocytes; ND 57 before YFV | 260.376 | 88 |
GSM1256993 | Yellow fever vaccinated NDs; Group 9: CD16pos, resident monocytes; ND 57 seven days after YFV | 257.192 | 87 |